NICE logo

BIMZELX is indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy.1

NICE recommendation applies to severe disease (PASI ≥ 10 or DLQI > 10) and when the disease has not responded to other systemic treatments, or when they are contraindicated or not tolerated.2

Blocking IL-17F in addition to il-17a results in superior inhibition of inflammatory responses vs blocking il-17a alone3

Off

Watch BIMZELX in action

BIMZELX is the first biologic for adult patients with moderate-to-severe plaque psoriasis designed to selectively and directly inhibit il-17a and il-17f1,4

On

Why is the mechanism of action important

IL-17F levels are approximately 3-fold higher than IL-17A in psoriatic skin.5

Pre-clinical data shows that BIMZELX provides more complete inhibition of the IL-17F and IL-17A pathway compared with blocking IL-17A alone.3,6 The clinical relevance of this data is unknown.

What’s more, BIMZELX inhibits IL-17F and IL-17A that can come from IL-23-dependent and independent sources, both of which contribute to inflammation in psoriasis.6

Inhibitors
Inhibitors
Zoom Icon

BIMZELX inhibits IL-17A and IL-17F – including both homodimers and the heterodimer-from interacting with the IL-17 receptor complex*3,4

Sizes of cytokines indicates higher expression level of IL-17F vs IL-17A in psoriatic skin.4

*Mechanism based on in vitro and human studies3,6

Abbreviations

IL, interleukin; IL-17 RA, interleukin 17 receptor A; IL-17 RC, interleukin 17 receptor C

On

References

References

  1. Bimzelx Summary of Product Characteristics.
  2. National Institute for Health and Care Excellence. 2021. Final Appraisal Document. Bimekizumab for treating moderate to severe plaque psoriasis.
  3. Glatt S, Baeten D, Baker T, et al. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation. Ann Rheum Dis. 2018;77(4):523-532.
  4. Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021;397(10272):487-498.
  5. Kolbinger F, Loesche C, Velentic MA, et al. β -Defensin 2 is a responsive biomarker of IL-17A-driven skin pathology in patients with psoriasis. J Allergy Clin Immunol. 2021;139(3):923-923.e8.
  6. Cole S, Murray J, Simpson C, et al. Interleukin (IL)-12 and IL-18 synergize to promote MAIT cell IL-17A and IL-17F production independently of IL-23 signaling. Front lmmunol. 2020;11:585134.
On

CHALLENGE EXPECTATIONS

Report adverse events

Adverse events should be reported. Reporting forms and information can be found at www.yellowcard.mhra.gov.uk and hpra.ie/homepage/about-us/report-an-issue.

Adverse events should also be reported to UCB Pharma Ltd Email: UCBCares.UK@ucb.com and UCBCares.IE@ucb.com.

Feature requests

Help us to grow our resource the way you want it to grow.

Get in touch now

Date of preparation: August 2021
IE-P-BK-PSO-2100056